| Cardiovascular Function and Risk Factors | Lifetime | 157 | ES 2 | 99.68 |
| Heart Failure Treatment and Management | Lifetime | 94 | ES 1 | 99.64 |
| Cardiac pacing and defibrillation studies | Lifetime | 125 | ES 4 | 99.53 |
| Tissue Engineering and Regenerative Medicine | Lifetime | 119 | ES 2 | 99.14 |
| Cardiac Structural Anomalies and Repair | Lifetime | 327 | ES 5 | 98.97 |
| IL-33, ST2, and ILC Pathways | Lifetime | 116 | ES 1 | 98.81 |
| Cardiac Fibrosis and Remodeling | Lifetime | 89 | ES 3 | 98.48 |
| Cardiac electrophysiology and arrhythmias | Lifetime | 478 | ES 6 | 98.78 |
| Potassium and Related Disorders | Lifetime | 76 | ES 1 | 98.22 |
| Mechanical Circulatory Support Devices | Lifetime | 416 | ES 2 | 98.24 |
| Atrial Fibrillation Management and Outcomes | Lifetime | 852 | ES 26 | 98.06 |
| Mesenchymal stem cell research | Lifetime | 586 | ES 6 | 97.33 |
| Acute Myocardial Infarction Research | Lifetime | 609 | ES 23 | 98.21 |
| Diabetes Treatment and Management | Lifetime | 629 | ES 5 | 97.76 |
| Cardiac Arrhythmias and Treatments | Lifetime | 977 | ES 20 | 97.70 |
| Electrospun Nanofibers in Biomedical Applications | Lifetime | 882 | ES 16 | 97.28 |
| GDF15 and Related Biomarkers | Lifetime | 109 | ES 2 | 93.33 |
| Congenital heart defects research | Lifetime | 698 | ES 10 | 95.27 |
| Galectins and Cancer Biology | Lifetime | 758 | ES 12 | 93.97 |
| Pericarditis and Cardiac Tamponade | Lifetime | 313 | ES 10 | 92.94 |
| Heart rate and cardiovascular health | Lifetime | 353 | ES 3 | 81.83 |
| Cardiovascular Function and Risk Factors | 2021-2025 | 13 | ES 1 | 99.91 |
| Cardiac pacing and defibrillation studies | 2021-2025 | 9 | ES 1 | 99.82 |
| Heart Failure Treatment and Management | 2021-2025 | 20 | ES 1 | 99.86 |
| Cardiac Structural Anomalies and Repair | 2021-2025 | 32 | ES 2 | 99.39 |
| Cardiac Fibrosis and Remodeling | 2021-2025 | 10 | ES 2 | 97.74 |
| Diabetes Treatment and Management | 2021-2025 | 128 | ES 2 | 98.57 |
| Cardiac Valve Diseases and Treatments | 2021-2025 | 214 | ES 11 | 98.55 |
| Potassium and Related Disorders | 2021-2025 | 33 | ES 1 | 97.12 |
| Viral Infections and Immunology Research | 2021-2025 | 151 | ES 3 | 93.76 |
| Cardiomyopathy and Myosin Studies | 2021-2025 | 227 | ES 10 | 94.38 |
| Cardiac Imaging and Diagnostics | 2021-2025 | 764 | ES 22 | 95.24 |
| Congenital Heart Disease Studies | 2021-2025 | 370 | ES 1 | 93.87 |
| Mechanical Circulatory Support Devices | 2021-2025 | 482 | ES 7 | 94.17 |
| Pulmonary Hypertension Research and Treatments | 2021-2025 | 339 | ES 8 | 93.33 |
| GDF15 and Related Biomarkers | 2021-2025 | 50 | ES 5 | 88.36 |
| Acute Myocardial Infarction Research | 2021-2025 | 692 | ES 21 | 92.19 |
| Hemodynamic Monitoring and Therapy | 2021-2025 | 374 | ES 8 | 89.00 |
| Heart Rate Variability and Autonomic Control | 2021-2025 | 792 | ES 24 | 88.19 |
| Infective Endocarditis Diagnosis and Management | 2021-2025 | 784 | ES 48 | 90.72 |
| Tissue Engineering and Regenerative Medicine | 2021-2025 | 511 | ES 15 | 86.55 |
| Cardiovascular Effects of Exercise | 2021-2025 | 964 | ES 54 | 81.82 |
| Amyloidosis: Diagnosis, Treatment, Outcomes | 2021-2025 | 929 | ES 35 | 75.94 |
| Electrolyte and hormonal disorders | 2021-2025 | 447 | ES 14 | 73.24 |
| IL-33, ST2, and ILC Pathways | 2021-2025 | 988 | ES 15 | 73.32 |
| Cardiac Ischemia and Reperfusion | 2021-2025 | 618 | ES 15 | 67.84 |
| Pericarditis and Cardiac Tamponade | 2021-2025 | 469 | ES 16 | 61.71 |
| Erythropoietin and Anemia Treatment | 2021-2025 | 654 | ES 25 | 59.82 |
| Signaling Pathways in Disease | 2021-2025 | 960 | ES 19 | 45.47 |
| Heart rate and cardiovascular health | 2021-2025 | 198 | ES 5 | 43.05 |
